The U.S. Food and Drug Administration's Mini‐Sentinel program: status and direction

The Mini‐Sentinel is a pilot program that is developing methods, tools, resources, policies, and procedures to facilitate the use of routinely collected electronic healthcare data to perform active surveillance of the safety of marketed medical products, including drugs, biologics, and medical devices. The U.S. Food and Drug Administration (FDA) initiated the program in 2009 as part of its Sentinel Initiative, in response to a Congressional mandate in the FDA Amendments Act of 2007.

[1]  R. Platt,et al.  Developing the Sentinel System--a national resource for evidence development. , 2011, The New England journal of medicine.

[2]  E. Perencevich,et al.  A systematic review of validated methods for identifying infection related to blood products, tissue grafts, or organ transplants using administrative data , 2012, Pharmacoepidemiology and drug safety.

[3]  R. Carnahan,et al.  A systematic review of validated methods for identifying transfusion‐related ABO incompatibility reactions using administrative and claims data , 2012, Pharmacoepidemiology and drug safety.

[4]  M. Reynolds,et al.  A systematic review of validated methods for identifying erythema multiforme major/minor/not otherwise specified, Stevens–Johnson Syndrome, or toxic epidermal necrolysis using administrative and claims data , 2012, Pharmacoepidemiology and Drug Safety.

[5]  R. Carnahan,et al.  A systematic review of validated methods for identifying transfusion‐related sepsis using administrative and claims data , 2012, Pharmacoepidemiology and drug safety.

[6]  David Madigan,et al.  When should case‐only designs be used for safety monitoring of medical products? , 2012, Pharmacoepidemiology and drug safety.

[7]  J. Pearl.  Invited commentary: understanding bias amplification. , 2011, American journal of epidemiology.

[8]  R. Carnahan,et al.  A systematic review of validated methods for identifying lymphoma using administrative data , 2012, Pharmacoepidemiology and drug safety.

[9]  M. Granner,et al.  A systematic review of validated methods for identifying seizures, convulsions, or epilepsy using administrative and claims data , 2012, Pharmacoepidemiology and drug safety.

[10]  L. Tamariz,et al.  A systematic review of validated methods for identifying ventricular arrhythmias using administrative and claims data , 2012, Pharmacoepidemiology and drug safety.

[11]  Thomas P. Gross,et al.  The US Food and Drug Administration's Sentinel Initiative: Expanding the horizons of medical product safety , 2012, Pharmacoepidemiology and drug safety.

[12]  L. Tamariz,et al.  A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data , 2012, Pharmacoepidemiology and Drug Safety.

[13]  Andrea J Cook,et al.  Statistical approaches to group sequential monitoring of postmarket safety surveillance data: current state of the art for use in the Mini‐Sentinel pilot , 2012, Pharmacoepidemiology and drug safety.

[14]  Jerry H. Gurwitz,et al.  Mini-Sentinel Systematic Evaluation of Health Outcome of Interest Definitions for Studies Using Administrative and Claims Data: Heart Failure , 2012 .

[15]  Jerry H. Gurwitz,et al.  A systematic review of validated methods for identifying heart failure using administrative data , 2012, Pharmacoepidemiology and drug safety.

[16]  Michael Nguyen,et al.  The Food and Drug Administration's Post‐Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise , 2012, Pharmacoepidemiology and drug safety.

[17]  Malcolm Maclure,et al.  Design considerations in an active medical product safety monitoring system , 2012, Pharmacoepidemiology and drug safety.

[18]  Andrea J Cook,et al.  Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data , 2012, Pharmacoepidemiology and drug safety.

[19]  Brian Sauer,et al.  Guidelines for good database selection and use in pharmacoepidemiology research , 2012, Pharmacoepidemiology and drug safety.

[20]  R. Carnahan,et al.  Mini‐Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative and claims data: methods and lessons learned , 2012, Pharmacoepidemiology and drug safety.

[21]  M. Reynolds,et al.  A systematic review of validated methods for identifying anaphylaxis, including anaphylactic shock and angioneurotic edema, using administrative and claims data , 2012, Pharmacoepidemiology and drug safety.

[22]  Philip Rotella,et al.  A systematic review of validated methods for identifying acute respiratory failure using administrative and claims data , 2012, Pharmacoepidemiology and drug safety.

[23]  Marsha A Raebel,et al.  Design considerations, architecture, and use of the Mini‐Sentinel distributed data system , 2012, Pharmacoepidemiology and drug safety.

[24]  Mark Olfson,et al.  A systematic review of validated methods for identifying suicide or suicidal ideation using administrative or claims data , 2012, Pharmacoepidemiology and drug safety.

[25]  Philip Rotella,et al.  A systematic review of validated methods for identifying hypersensitivity reactions other than anaphylaxis (fever, rash, and lymphadenopathy), using administrative and claims data , 2012, Pharmacoepidemiology and drug safety.

[26]  Sengwee Toh,et al.  A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent , 2012, Pharmacoepidemiology and drug safety.

[27]  Sengwee Toh,et al.  Design for validation of acute myocardial infarction cases in Mini‐Sentinel , 2012, Pharmacoepidemiology and drug safety.

[28]  James Floyd,et al.  A systematic review of validated methods for identifying atrial fibrillation using administrative data , 2012, Pharmacoepidemiology and drug safety.

[29]  Barbara Evans,et al.  A policy framework for public health uses of electronic health data , 2012, Pharmacoepidemiology and drug safety.

[30]  Sebastian Schneeweiss,et al.  Using high‐dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system , 2012, Pharmacoepidemiology and drug safety.

[31]  M. Reynolds,et al.  A systematic review of validated methods for identifying pulmonary fibrosis and interstitial lung disease using administrative and claims data , 2012, Pharmacoepidemiology and drug safety.

[32]  Richard Platt,et al.  The organizational structure and governing principles of the Food and Drug Administration's Mini‐Sentinel pilot program , 2012, Pharmacoepidemiology and drug safety.

[33]  Mohit Bhandari,et al.  A systematic review of validated methods for identifying orthopedic implant removal and revision using administrative data , 2012, Pharmacoepidemiology and drug safety.

[34]  R. Carnahan,et al.  Mini‐Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative data: summary of findings and suggestions for future research , 2012, Pharmacoepidemiology and drug safety.

[35]  J. Gurwitz,et al.  A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data , 2012, Pharmacoepidemiology and drug safety.

[36]  R. Platt,et al.  The new Sentinel Network--improving the evidence of medical-product safety. , 2009, The New England journal of medicine.

[37]  J. Myers,et al.  Effects of adjusting for instrumental variables on bias and precision of effect estimates. , 2011, American journal of epidemiology.

[38]  R. Carnahan,et al.  A systematic review of validated methods for identifying pancreatitis using administrative data , 2012, Pharmacoepidemiology and drug safety.

[39]  Mark Olfson,et al.  A systematic review of validated methods for identifying depression using administrative data , 2012, Pharmacoepidemiology and drug safety.